
Urology Specialist Registrar in London, UK | Uro-Oncology & Academics | Tennis NUT 🎾 | Former @BJUIjournal Section Editor @BURSTurology VC |
London, England
Joined January 2012
- Tweets11.9K
- Following2.3K
- Followers1.3K
- Likes15.5K
Meg Kulkarni 💙 retweeted
Are you still describing AEs with the term "TOXICITY"? Even when publishing papers reporting graded AEs? If so, I recommend reviewing this notification from @theNCI and noting the date it was released.
Meg Kulkarni 💙 retweeted
ESMO 2026 GU recap: PROTEUS, DASL-HiCaP, CAPItello-281, VOLGA, POTOMAC, PE-PE, and LITESPARK-011.
The prostate, bladder, and kidney cancer data to know ↓
Swipe through →
hubs.li/Q04D5dZb0
#ESMO26 #GUOnc
Meg Kulkarni 💙 retweeted
🚨 #CurrentUrology Spotlight
Spermidine and male infertility: beyond semen parameters?
A 60-man RCT found that adding spermidine (4 mg/day) for 3 months improved fertility-related quality of life and sleep quality. Improvements in semen parameters were not statistically significant.
🔗 doi.org/10.1097/CU9.00000000…
#UroSoMe #Andrology #MaleInfertility #SleepHealth
Meg Kulkarni 💙 retweeted
New BMJ Research: How effective is paravertebral blockade versus thoracic epidural during the perioperative period in reducing chronic post-thoracotomy pain?
bmj.com/content/395/bmj-2026…
Linked commentary
bmj.com/content/395/bmj-2026…
Meg Kulkarni 💙 retweeted
🔬 Do clinical trials truly represent the patients we treat every day?
Excited to share the latest publication developed within the PIONEER+ EAU UroEvidenceHub initiative!
📊 Using real-world data from 32,585 patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC), we assessed the applicability of 12 landmark randomized controlled trials.
🔎 Key findings:
Up to 55% of real-world patients would have been ineligible for individual pivotal trials.
55–60% met at least one exclusion criterion from the trials evaluated.
Anemia, heart failure, and renal impairment were among the most frequent reasons for exclusion.
Importantly, a substantial proportion of patients receiving trial-tested therapies in routine practice would not have qualified for the trials supporting their use.
💡 The take-home message?
Randomized trials tell us whether treatments work under controlled conditions. Real-world evidence helps us understand how applicable those findings are to the patients sitting in front of us.
We need more inclusive clinical trials, better integration of real-world evidence, and treatment decisions that reflect patient complexity not just disease characteristics.
@GGandaglia @Sevans_axelsson @NICOLETTIRosse1 @dr_rajwa @poolik @Uroweb
#ProstateCancer #RealWorldEvidence #PIONEERplus #mHSPC
sciencedirect.com/science/ar…
Meg Kulkarni 💙 retweeted
What else could be more interesting on your Tuesday evening than @Uroweb webinar covering sperm selection, varicocele tx & hormone selecting @jovcorona @CarloBettocchi @MikkelFode @DinkSmit #JonathanRamsey?? Still time to register webinars.uroweb.org/EAU/webi…
Meg Kulkarni 💙 retweeted
Our campaign is about reducing burnout, returning the time we had to actually fix our services and regaining comparable pay. Here's me explaining on GBNews. #DemandBetter
Meg Kulkarni 💙 retweeted
We have recoded BAUS on Demand to improve functionality. Previous conference videos for @BAUSurology members. The views and likes counters are now working. A lot more content coming soon. Check it out:
baus.org.uk/mybaus/education…
Meg Kulkarni 💙 retweeted
A terrible loss. She was the world's premiere infectious disease reporter -- an icon for all of us in public health science and journalism alike.
It is hard to believe that Helen Branswell has passed away. Just heartbreaking.
On January 4, 2020, Helen wrote STAT's first story on a mystery pneumonia outbreak in China. She saw the pandemic coming well before anyone was paying attention.
Helen was a journalist who knew more than most of the experts she interviewed. She understood the science, the history and the politics of every outbreak she covered. She asked the hardest (and best) questions and never let me get away with a vague answer
Experts learned from her. I certainly did
It's hard to imagine a world of pandemics, biological threats and so much more without a Helen Branswell to explain it all.
statnews.com/2026/10/13/hele…
Meg Kulkarni 💙 retweeted
Dehiscence, infection, seroma, haematoma (DISH): development and validation of a new classification of surgical site outcomes
➡️ doi.org/10.1093/bjs/znag112
The proposed cross-specialty, global DISH Classification facilitates more comprehensive surveillance and audit of SSOs in clinical practice and research, by standardizing reporting of all relevant grades of clinical presentation and management of SSOs
Work by Giles Bond-Smith , Marja A Boermeester , David J Leaper , Philip L Russo , Antonia F Chen , the SSO Working Group Authors , the SSO Expert Panel , the SSO Validation Study Panel
#SoMe4Surgery #MedTwitter #SurgEd #Surgery @RCPSGTrainees @aecirujanos @SEIQuirurgica @iss_sic #MedicalTechniques @BJSAcademy @young_bjs @BJSOpen @evanscolorectal @robhinchliffe1 @bplwijn @MalinASund @nfmkok @TejedorPat @paulo_sutt @PVaughanShaw @JJEarnshaw @juliomayol @ksoreide #some4hpb #some4tpl @DPCG_official @pancreatitis_nl @PancreasClub #PancreasClub2023 #PancreaticCancer #Pancreatitis #HCC @PanCAN #PanCANawareness @EurPancClub @P_C_E_ @dice_europe #PancreaticCancer #cholangiocarcinoma #HPBSurgery #GallbladderCancer #Oncology #LiverSurgery #colorectalsurgery #StepUp4CRC @FightCRC @ACPGBI #ERAS @dice_europe #Crohn #proctology @Dukes_Club @ACPGBI_EduTrain @AECP_FAECP @PelvExGroup @escp_tweets @YouESCP #TeachMeColoproctology
#Some4COLoprocto #some4UGI #uppergi #esophagealcancer #gastriccancer #reflux @ISDE_net @Augishealth @roux_group @T4UGIS @SARONG_Trial @YoungIFSO #bariatricsurgery
Meg Kulkarni 💙 retweeted
I have noticed an up tick in PA anons and PA supporting accounts coming to give an opinion-on my feed- about my views on @lengreview PA protocols.
To help you, I have 3 things to say.
1. I don't have any influence in the system, I am not part of Council @RCPhysicians (powers that be terminated my time).
I have no voice that anyone takes much note of- especially in @NHSE_WTE @NHSEngland circles.
There's a reason I am not in the @HSJnews Non-white influential people list- it's because I don't have influence. That is a fact.
So don't worry at all about my view.
2. Making references to my recent loss in a derogatory way is more a reflection of your upbringing or lack of it.
I spend enough time nowadays in darkness- you can't make it worse.
Avoid it- you never know what happens in your own life in the future
3. You should have the same approach as I do to pro-PA views. I literally don't care at this point. I believe the way in which many have tried and are trying to use PAs is dangerous to the public. You don't agree.
Fine- it's a democracy.
But I will say what I believe to be true.
Also- if you bring heat to a conversation?
Don't flounce off when you get smoked in return.
Refer to point 3- I don't care about your opinion at this point
I hope that helps
Thanks and much love
Partha
Meg Kulkarni 💙 retweeted
Lymphocele cited as major reason in guidelines to avoid LND in prostate cancer. Here we show most almost all lymphoceles (42/43) come from Cloquet's node, which should not be removed during LND. auajournals.org/doi/10.1097/…
Meg Kulkarni 💙 retweeted
Devastating news 💔
Rest in peace dear Rachna.
medicine.arizona.edu/news/20…
Meg Kulkarni 💙 retweeted
Any tips at #SMSNA26 for a replacement suture for those doing EDVs? I can’t get hold of Corza 10-0 double ended sutures that are 2.5cm length..only 30cm which is awful! Help! @donwglee can you ask @DrLipshultzTips @ScottLundyMDPhD @raevti @SaveYourSexLife @rbarbosa91 @dr_wardsam
Epididymovasostomy…. An excellent option for obstructive azoospermia in the right hands. Difficult to say, harder to spell and takes many years to perfect the surgery. Looking forward to sharing my video, discussing patients and tips/tricks for surgery at #WMSM2026 Friday 27th
Meg Kulkarni 💙 retweeted
If you're trying to build support for ergonomics at your institution, start somewhere practical:
• Reframe the problem
• Bring local data
• Find partners
• Start with one specific problem
• Don't stop at education
@https://surgicalergonomics.com/podcast/
🤖 Made with AI
Meg Kulkarni 💙 retweeted
🔬 PROTEUS y cáncer de próstata de alto riesgo: ¿estamos comparando las mismas poblaciones?
El ensayo PROTEUS ha abierto una nueva etapa en el tratamiento del cáncer de próstata de alto riesgo, demostrando beneficios de añadir apalutamida a la terapia de deprivación androgénica en el contexto perioperatorio.
Sin embargo, surge una pregunta fundamental: ¿representan las cohortes retrospectivas de pacientes elegibles para PROTEUS a la población realmente incluida en el ensayo?
📊 En nuestra carta destacamos tres aspectos:
🔹 Las diferencias entre los criterios de inclusión de un ensayo y las clasificaciones de riesgo de las guías EAU/NCCN pueden modificar significativamente la categorización de los pacientes.
🔹 La población incluida en PROTEUS presentaba características clínicas y patológicas más desfavorables que las observadas en algunas cohortes retrospectivas reconstruidas.
🔹 La intensificación terapéutica debe acompañarse de una selección adecuada de pacientes, evitando extrapolaciones que puedan conducir al sobretratamiento.
🎯 Ser elegible para un ensayo no significa necesariamente representar a la población finalmente incluida.
En una era de creciente intensificación terapéutica, interpretar correctamente la evidencia es tan importante como generar nuevos datos.
🔗 sciencedirect.com/science/ar…
@Lara__Rodriguez @GGiannarini @foxal72
#ProstateCancer
Meg Kulkarni 💙 retweeted
Comments on the protocol for PAs:
Regards the people who have done this.
It's no different to what I saw when RCP was making their interim document of scope.
A few of us stopped it from a complete slide at that point- and this panel doesn't have a dissenting voice- so it's mostly an echo chamber IMO.
FWIW?
I respect Gill Leng- and she has been-IMO- bench pressed by a skewed group.
It is why she is asking for as many people as possible to comment on this.
If we-as doctors- we want to support her and @lengreview recommendations, we support her through organisations as best as we can.
First the good news:
1. With the @TheBMA having put the PA protocol document in the public domain?
The @RCPhysicians is saved the hassle of mulling over whether to open it up formally.
Now that it's open, let Members & Fellows decide whether they want to take this level of supervisory responsibility.
Let the wider democracy give their views
2. It's a national scope work- so we are finally moving away from the nonsense of 'local scope'
Now the rest:
1. My personal view?
It's a flat No from secondary care perspective
No one has that level of supervisory capacity as stated in document due to job plan constraints.
And we have the 'Medical Education & Training Review' yet to land @DacreJane
Which means- we will have lesser trained people seeing undifferentiated patients- and cause harm.
2. In my opinion, it should be rejected by RCP et al- but I don't speak for all.
Write to your College.
If you- as a Resident Doctor- or Senior- feel this is ok?
Write too.
That is my view- and I will not want any of my loved ones to be seen by a PA as per this protocol.
I have the privilege to avoid that.
Question is- do you.
This document goes nowhere without support of @TheBMA @RCPhysicians @rcgp et al
I can guarantee you that @DHSCgovuk will not take on a pitched battle if all doctor organisations- the ones being asked to be the liability sponge- says 'No'
Over to all of you.
I know it feels tiring sometimes- battling the machine- while trying to improve patient safety
Yet- You only lose when you give up.
@mmamas1973 @djnicholl @Mumtaz_Patel_1 @OGMustafa @VictoriaTzB @SwordsFrankie
The questions must be asked
Less obfuscation, more transparency
Formal ask in place
Over to you @RCPhysicians
As a Fellow, we should be able to comment on the protocols as suggested by @lengreview
The 'era of transparency' should mean exactly that
@djnicholl @mmamas1973
Meg Kulkarni 💙 retweeted
Join the RSM Urology Section for a meeting exploring trauma, emergency urology and the evolving landscape of urgent urological care.
Find out more: rsm.ac.uk/events/urology/202…
Friday 16 October 2026 📅
9:00am to 5:00 pm BST⏲️
RSM, London📍
Meg Kulkarni 💙 retweeted
“Bridging the PSMA PET/CT access gap in prostate cancer: evidence, barriers, and priorities for implementation” addresses an increasingly challenge: strong evidence and guideline recommendations do not necessarily translate into timely and equitable access for patients.
🎯PSMA PET/CT has transformed prostate cancer imaging. However, access remains heterogeneous across countries, regions and institutions, with barriers including reimbursement, nuclear medicine capacity, radiopharmaceutical logistics, waiting times and variable referral pathways.
🇪🇺 Exploratory European data suggest that real-world use remains below the estimated eligible population, highlighting an implementation gap between evidence, recommendations and clinical practice.
🎯 Priorities for implementation include guideline-based eligibility, harmonised reimbursement, regional referral networks, adequate imaging and reporting capacity, multidisciplinary collaboration, and measurable access indicators.
The next challenge for PSMA PET/CT is not proving its value, but ensuring that eligible patients can access the right imaging at the right time, regardless of geography or institution.
#ProstateCancer #PSMAPET #Urology
link.springer.com/article/10…
@MRoupret @wjurol @InfoAeu @UrologiaClinico
Meg Kulkarni 💙 retweeted
The basic training of a doctor reduced to a poster due to the proliferation of non medically trained people seeing undifferentiated patients - if u have to use this poster, you are not trained medically and you should not be seeing patients @NHS



































